BioTuesdays

Category - Developments

Profound Medical Logo

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound. Analyst Rahul Sarugaser writes that...

CymaBay Therapeutics

CymaBay reports positive seladelpar data in PBC

CymaBay Therapeutics (NASDAQ:CBAY) presented new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a type of liver disease that damages...